Prognosis analysis for RFS in LOGpc demonstrated that the elevated APLN expression is associated with poor RFS in LGG patients with seizure history (p = 9.4E − 3; HR: 1.8683; 95% CI: 1.1654-2.995; Figure S1(a)), with primary tumor (p = 0.0237; HR: 1.5633; 95% CI: 1.0613-2.3027; Figure S1(b)), with targeted molecular therapy (p = 1.8E − 3; HR: 2.0505; 95% CI: 1.3049-3.2221; Figure S1(c)), and with oligodendroglioma (p = 0.012; HR: 2.1767; 95% CI: 1.1864-3.9936; Figure S1(d)). Here, APLN is linked to oligodendroglioma.